Inhibitor Therapeutics (INTI) Profit After Tax (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Profit After Tax came in at -$700000.0 in Q1 2026, down 10.61% YoY from -$783097.9 in Q1 2025, and up 45.96% on a QoQ basis from -$1.3 million in Q4 2025.
Inhibitor Therapeutics (INTI) Profit After Tax (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Profit After Tax data on file, last reported at -$700000.0 in Q1 2026.
- Quarterly Profit After Tax fell 10.61% year-over-year to -$700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 2.44% YoY) and the FY2025 annual result came in at -$3.3 million, up 1.16% from the prior year.
- Profit After Tax improved to -$700000.0 in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $12.4 million in Q4 2022 to a low of -$1.4 million in Q4 2024.
- A 5-year average of $102385.7 and a median of -$659942.0 in 2025 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax jumped 36929.65% — and 2023, when it sank 755.64%.
- Tracing INTI's Profit After Tax over 5 years: stood at $12.4 million in 2022, then sank by 109.44% to -$1.2 million in 2023, then slipped by 21.81% to -$1.4 million in 2024, then gained by 8.9% to -$1.3 million in 2025, then soared by 45.96% to -$700000.0 in 2026.
- The last three Profit After Tax figures came in at -$700000.0 (Q1 2026), -$1.3 million (Q4 2025), and -$712184.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -613,933.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -700,000.00 |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | -712,184.00 |
| Jun 30, 2025 | -659,942.00 |
| Mar 31, 2025 | -632,846.00 |
| Dec 31, 2024 | -1.42 Mn |
| Sep 30, 2024 | -730,957.00 |
| Jun 30, 2024 | -501,690.00 |
| Mar 31, 2024 | -684,711.00 |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -664,760.00 |
| Jun 30, 2023 | -654,521.00 |
| Mar 31, 2023 | -539,596.00 |
| Dec 31, 2022 | 12.36 Mn |
| Sep 30, 2022 | -77,692.00 |
| Jun 30, 2022 | -77,567.00 |
| Mar 31, 2022 | -98,910.00 |
| Dec 31, 2021 | -33,561.00 |
| Sep 30, 2021 | -121,463.00 |
| Jun 30, 2021 | -66,182.00 |